<DOC>
	<DOCNO>NCT00643877</DOCNO>
	<brief_summary>The purpose study investigate whether preoperative hepatic regional arterial chemotherapy able prevent liver metastasis improve overall survival patient receive curative colorectal cancer resection .</brief_summary>
	<brief_title>Trial Preoperative Hepatic Regional Arterial Chemotherapy ( PHRAC ) Prevent Postoperative Liver Metastasis Colorectal Cancer</brief_title>
	<detailed_description>We administer FUDR , MMC Oxaliplatin preoperative hepatic regional arterial chemotherapy ( PHRAC ) patient Stage II Stage III colorectal cancer without apparent liver metastasis base thorough preoperative evaluation . The study endpoints disease-free survival , overall survival , liver metastasis-free survival evaluate intent-to-treat analysis .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>age &lt; 75 year histologically proven adenocarcinoma colon rectum severe major organ dysfunction WHO performance status 0 1 prior cancer therapy Stage II ( T34 , N0 , M0 ) Stage III ( T04 , N12 , M0 ) disease ( accord 1997 revision International Union Against Cancer TNM stag system ) determine preoperative evaluation include colonoscopy abdominal compute tomography ( CT ) scan age &gt; = 75 severe major organ dysfunction WHO performance status &gt; 1 prior cancer therapy Stage I Stage IV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Colorectal Neoplasms</keyword>
	<keyword>Regional</keyword>
	<keyword>Liver</keyword>
	<keyword>Neoplasm Metastasis</keyword>
</DOC>